Kalaris Therapeutics (KLRS)
Develops TH103 for neovascular and exudative retinal diseases.
$3.76
Pre-market−0.14 (−3.60%)
At close$3.90(−0.50%)
Something off on this page? Send us feedback.
Next report
Nov 11, 2026
in 69 days
EPS estimate
−$0.52
Revenue estimate
—
Fiscal quarter
Q3 FY26
EPSReportedEstimate
May '25Aug '25Nov '25Mar '26May '26Aug '26Aug '26Nov '26
Reported−$2.52−$0.61−$0.64−$0.44−$0.46−$0.48−$0.48Pending
Estimate−$0.78−$0.51−$0.66−$0.56−$0.52−$0.50−$0.50−$0.52
Surprise−223.1%−19.6%+3.0%+21.4%+11.5%+3.0%+4.0%—
RevenueReportedEstimate
May '25Aug '25Nov '25Mar '26May '26Aug '26Aug '26Nov '26
Reported———————Pending
Estimate————————
Surprise————————
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.52 | — | — |
| Aug 2026 | −$0.50 | −$0.48 | +4.0% |
| Aug 2026 | −$0.50 | −$0.48 | +3.0% |
| May 2026 | −$0.52 | −$0.46 | +11.5% |
| Mar 2026 | −$0.56 | −$0.44 | +21.4% |
The latest year is open to everyone — the 28 quarters behind it read with an account. Sign in | |||
| Nov 2025 | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Jun 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Dec 2023 | |||
| Sep 2023 | |||
| Jun 2023 | |||
| Mar 2023 | |||
| Dec 2022 | |||
| Sep 2022 | |||
| Jun 2022 | |||
| Mar 2022 | |||
| Dec 2021 | |||
| Sep 2021 | |||
| Jun 2021 | |||
| Mar 2021 | |||
| Dec 2020 | |||
| Sep 2020 | |||
| Jun 2020 | |||
| Mar 2020 | |||
| Dec 2019 | |||
| Sep 2019 | |||
| Jun 2019 | |||
| Mar 2019 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Nov 11, 2026 | −$0.52 | — | — | — | — | — | — |
| Aug 12, 2026 | −$0.50 | −$0.48 | +4.0% | — | — | — | −0.8% |
| Aug 11, 2026 | −$0.50 | −$0.48 | +3.0% | — | — | — | +0.8% |
| May 12, 2026 | −$0.52 | −$0.46 | +11.5% | — | — | — | +0.8% |
| Mar 17, 2026 | −$0.56 | −$0.44 | +21.4% | — | — | — | −11.6% |
The latest year is open to everyone — the 28 quarters behind it read with an account. Sign in | |||||||
| Nov 12, 2025 | |||||||
| Aug 13, 2025 | |||||||
| May 14, 2025 | |||||||
| Mar 7, 2025 | |||||||
| Nov 12, 2024 | |||||||
| Jun 30, 2024 | |||||||
| May 13, 2024 | |||||||
| Mar 31, 2024 | |||||||
| Dec 31, 2023 | |||||||
| Sep 30, 2023 | |||||||
| Jun 30, 2023 | |||||||
| Mar 31, 2023 | |||||||
| Dec 31, 2022 | |||||||
| Sep 30, 2022 | |||||||
| Jun 30, 2022 | |||||||
| Mar 31, 2022 | |||||||
| Dec 31, 2021 | |||||||
| Sep 30, 2021 | |||||||
| Jun 30, 2021 | |||||||
| Mar 31, 2021 | |||||||
| Dec 31, 2020 | |||||||
| Sep 30, 2020 | |||||||
| Jun 30, 2020 | |||||||
| Mar 31, 2020 | |||||||
| Dec 31, 2019 | |||||||
| Sep 30, 2019 | |||||||
| Jun 30, 2019 | |||||||
| Mar 31, 2019 | |||||||